ALSO NOTED: Does FDA scrutinize new generics enough?; BMS shops baby-food business;

> Are generics as good as brand-name drugs? The Los Angeles Times questions the FDA's generic-approval process, which leans lightly on drug makers. Report

> Bristol-Myers Squibb is looking to get out of the baby food business, scouting out potential buyers for the $7 billion to $9 billion unit. Report

> Potential buyers have been touring Pfizer's Ann Arbor, MI, facility, which is set to close in 2009. Report

> India's Sun Pharmaceutical Industries got FDA approval for its copycat form of AstraZeneca's Ethyol, used to reduce kidney damage in patients with advanced ovarian cancer. Report

> Teva is planning an aggressive move into biogenerics. Report

> In an interview, Celgene CEO Sol Barer laid out some of the basics in how it will integrate operations with Pharmion, a biotech Celgene paid $2.9 billion for. Report

And Finally... A new book takes Big Pharma to task for marketing tactics. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.